

Perrigo launches nasal spray 'Flonase'

01 June 2016 | News | By BioSpectrum Bureau

Perrigo launches nasal spray 'Flonase'



Perrigo and its partner West-Ward Pharmaceuticals Corp. has announced the US Food and Drug Administration has approved, and that Perrigo has launched, fluticasone propionate nasal spray USP, 50 mcg per spray, the store brand equivalent to Flonase. This product is packaged and marketed as store brand or retailer 'own label' brands and provides consumers with a high-quality, value alternative to Flonase.

Flonase (fluticasone propionate nasal spray USP, 50 mcg per spray) is indicated for the temporary relief of hay fever or other upper respiratory allergies in adult and pediatric patients 4 years of age and older. Combined store brand and national brand sales for the twelve months ending May 2016 were \$343 million.

Perrigo's CEO Mr John T. Hendrickson stated, "This product approval and launch demonstrates the power of Perrigo's OTC platform. Our team has made significant efforts to bring this important product to our customers and consumers in the U.S. Important product launches like the store brand switch of fluticasone are what drive the Perrigo advantage by providing our consumers with high quality, value alternatives in important treatment categories."